<DOC>
	<DOCNO>NCT00335699</DOCNO>
	<brief_summary>The primary objective study compare effect rosuvastatin 10mg atorvastatin 10mg percentage reduction LDL-C Subjects metabolic syndrome 6 week treatment .</brief_summary>
	<brief_title>Korean Rosuvastatin Effectiveness Study Nondiabetic Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Metabolic syndrome patient ; Presence 3 follow : Abdominal obesity ( waist circumference ) : men &gt; 90cm ( 36 inch ) , woman &gt; 80cm ( 32 inch ) Triglycerides ≥ 150 mg/dL ( 1.70 mmol/L ) HDLC : men &lt; 40 mg/dL ( 1.04 mmol/L ) , woman &lt; 50 mg/dL ( 1.3 mmol/L ) BP ≥130/≥85 mmHg subject receive antihypertensive treatment Fasting blood glucose 110 mg dL ( 6.11 mmol/L ) 125 mg/dL ( 6.94 mmol.L ) Elevated LDLC concentration report within 4 week visit 1 follow ; ≥ 130 mg/dL ( 3.36 mmol/L ) &lt; 220 mg/dL ( 5.69 mmol/L ) statin naive subject ( subject take lipidlowering therapy know affect LDLC 4 week prior visit 1 ) ≥ 100 mg/dL ( 2.59 mmol/L ) &lt; 160 mg/dL ( 4.14 mmol/L ) subject take lipid lowering drug ( ) within 4 week visit 1 Triglyceride level &lt; 400 mg/dL ( 4.52 mmol/L ) Women childbearing potential use medically acceptable form chemical mechanical contraception . History know diabetes mellitus Use antihyperglycaemic medication . History serious hypersensitivity reaction HMGCoA reductase inhibitor , particular history myopathy . No CHD CHD Risk Equivalents 01 Risk factor Framingham 10Year risk &lt; 10 % . History heterozygous homozygous familial hypercholesterolaemia know type III hyperlipoproteinaemia ( familial dysbetalipoproteinaemia ) . Active arterial disease unstable angina pectoris , myocardial infarction , transient ischaemic attack ( TIA ) , cerebrovascular accident ( CVA ) , coronary artery bypass surgery ( CABG ) angioplasty within 2 month prior entry dietary lead period Uncontrolled hypothyroidism define thyroid stimulate hormone ( TSH ) &gt; 1.5 time upper limit normal ( ULN ) Visit 2 subject whose thyroid replacement therapy initiate within 3 month entry dietary leadin phase . Current active liver disease ( alanine aminotransferase [ ALT ] &gt; 2 x ULN ) severe hepatic impairment . Unexplained serum CK &gt; 3 time ULN ( e.g . due recent trauma , intramuscular injection , heavy exercise , etc ) . Serum creatinine &gt; 176 umol/L ( 2.0 mg/dL ) History alcohol , drug , abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Hypercholesterolemia nondiabetic metabolic syndrome</keyword>
</DOC>